Talphera (NASDAQ:TLPH) Trading Up 4.5% – Here’s Why

Shares of Talphera, Inc. (NASDAQ:TLPH) were up 4.5% during trading on Thursday . The stock traded as high as $0.8406 and last traded at $0.80. Approximately 126,395 shares traded hands during trading, a decline of 4% from the average daily volume of 131,947 shares. The stock had previously closed at $0.7652.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TLPH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a research report on Monday, April 20th. Westpark Capital began coverage on shares of Talphera in a research note on Thursday, April 30th. They issued a “buy” rating and a $3.00 price objective for the company. Finally, HC Wainwright initiated coverage on shares of Talphera in a report on Friday. They issued a “buy” rating and a $3.00 price objective for the company. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.00.

Talphera Stock Down 3.1%

The business’s 50-day moving average price is $0.81 and its 200 day moving average price is $0.95. The company has a market capitalization of $40.22 million, a P/E ratio of -2.50 and a beta of 0.76.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03.

Insiders Place Their Bets

In other Talphera news, CEO Vincent J. Angotti purchased 213,310 shares of the stock in a transaction on Friday, March 13th. The stock was acquired at an average cost of $0.59 per share, with a total value of $125,852.90. Following the completion of the purchase, the chief executive officer directly owned 800,705 shares of the company’s stock, valued at approximately $472,415.95. This trade represents a 36.31% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Talphera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC raised its holdings in shares of Talphera by 4.6% during the fourth quarter. AIGH Capital Management LLC now owns 4,661,502 shares of the company’s stock valued at $5,314,000 after acquiring an additional 206,957 shares in the last quarter. Rosalind Advisors Inc. raised its position in shares of Talphera by 118.9% in the 3rd quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock worth $3,917,000 after acquiring an additional 2,381,818 shares in the last quarter. Nantahala Capital Management LLC raised its position in shares of Talphera by 75.3% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after acquiring an additional 1,500,000 shares in the last quarter. Empery Asset Management LP bought a new position in shares of Talphera in the 4th quarter worth approximately $1,520,000. Finally, Cantor Fitzgerald L. P. bought a new position in shares of Talphera in the 4th quarter worth approximately $658,000. 37.67% of the stock is currently owned by institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.